Biree Andemariam, MD
Hematology & Oncology · Farmington, CTNPI 1396935136
Payments from drug & device makers
Across 428 payments — averaging $3759.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Global Blood Therapeutics, Inc.$875K
- Agios Pharmaceuticals, Inc.$219K
- Novartis$146K
- Vertex$77K
- Pfizer$76K
- Novo Nordisk Health Care AG$52K
- plus $165K from 19 others
Across 45 payments — averaging $955.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$22K
- Pfizer$11K
- Novartis$10K
- Novo Nordisk$125
What the payments were for
- Consulting fees$566,67488%
- Speaking & faculty fees$51,8358%
- Travel & lodging$22,3583%
- Food & beverage$4,8351%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Global Blood Therapeutics, Inc. | 114 | $874,712 |
| Agios Pharmaceuticals, Inc. | 106 | $218,743 |
| Novartis | 23 | $146,352 |
| Vertex | 36 | $76,793 |
| Pfizer | 39 | $76,085 |
| Novo Nordisk Health Care AG | 18 | $51,598 |
| Genetix Biotherapeutics Inc | 5 | $32,300 |
| Novo Nordisk | 13 | $26,700 |
| Sanofi | 11 | $25,847 |
| Novo Nordisk AS | 9 | $17,007 |
| Bioverativ Therapeutics Inc. | 11 | $12,240 |
| E.r. Squibb & Sons, L.L.C. | 6 | $10,682 |
| Genentech USA, Inc. | 6 | $8,121 |
| Merck | 9 | $7,111 |
| Sanofi US Services Inc. | 1 | $4,986 |
| Octapharma USA, Inc. | 1 | $4,000 |
| Omeros Corporation | 1 | $2,800 |
| F. Hoffmann-la Roche AG | 2 | $2,696 |
| HEMA Biologics, LLC | 1 | $2,500 |
| Terumo BCT, Inc. | 4 | $2,375 |
| GSK | 1 | $2,000 |
| Bayer | 2 | $1,120 |
| Tersera Therapeutics LLC | 1 | $1,110 |
| Emmaus Medical, Inc. | 7 | $1,065 |
| Seagen Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OXBRYTA$158,168
- PYRUKYND$105,879
- SKYSONA$32,300
- Zynteglo$32,300
- ADAKVEO$15,293
- HYMPAVZI$9,680
- NO PRODUCT DISCUSSED$8,308
- HEMLIBRA$8,091
- LYFGENIA$3,740
- TALZENNA$3,716
- narsoplimab$2,800
- SevenFact$2,500
- Spectra Optia Apheresis System$2,375
- KEYTRUDA$1,311
- QUZYTTIR$1,110
- Jivi$1,088
- Non-Covered Product$1,056
- Endari$833
- ELOCTATE$118
- ALPROLIX$110
How this compares
$1,608,956 in reported general payments places this provider in the 90th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Farmington
- Upendra HegdeFarmington$1M
- Swarup KumarFarmington$862K
- Aakash DesaiFarmington$822K
- Robert BonaFarmington$180K
- Susan TannenbaumFarmington$80K
- Oladipo ColeFarmington$44K
- Amer ZeidanNew Haven$15.5M
- Nataliya UbohaNew Haven$13.3M
- Michael CecchiniNew Haven$7.8M
- Richard FrankNorwalk$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.